| Name | Title | Contact Details |
|---|
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
PRC is a global leader in AAC Solutions including for individuals with speech disorders. *This group does not provide official technical support.
genetic Immunity is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celsion Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Biomed International is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.